OPAL FLOWERS: Open Payments
NPI 1023873247 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$903 in 41 payments from 15 companies in 2025. Trend: 2023 $68 · 2024 $600 · 2025 $903
Food & beverage: $903
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 8 | $242 |
| Alnylam Pharmaceuticals Inc. | 9 | $170 |
| Baxter Healthcare | 1 | $93 |
| BridgeBio Pharma, Inc. | 3 | $61 |
| Novo Nordisk Inc | 4 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
| PFIZER INC. | 3 | $56 |
| Merck Sharp & Dohme LLC | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $21 |
Products named: AMVUTTRA, UPTRAVI, STARLING SYSTEM, Attruby, Wegovy, JARDIANCE, VYNDAQEL, OPSYNVI.
Industry payments across AR — which companies pay providers there.
